Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Anti-MS4a4B treatment abrogates MS4a4B-mediated protection in T cells and ameliorates experimental autoimmune encephalomyelitis.
Medication withdrawal may be an option for a select group of patients in relapsing-remitting multiple sclerosis.
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.
Kalopanaxsaponin A Exerts Anti-Inflammatory Effects in Lipopolysaccharide-Stimulated Microglia via Inhibition of JNK and NF-κB/AP-1 Pathways.
Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome.
The Effects of "Pilates" Based Core Stability Training in Ambulant People With Multiple Sclerosis: A Multi-Centre, Randomised, Assessor-Blinded, Controlled Trial.
Development and implementation of microsimulation models of neurological conditions.
Lymphocytic hypophysitis associated with pediatric multiple sclerosis.
Activation of endogenous neural stem cells for multiple sclerosis therapy.
Cortical Lesions in Multiple Sclerosis: Clinical Relevance for a Hidden Disease Burden.
Radiolabeled anti-aquaporin-4 protein antibody imaging: a valuable method for determining neuromyelitis optica.
Detection of Antibodies against Human and Plant Aquaporins in Patients with Multiple Sclerosis.
"Nine" syndrome: A new neuro-ophthalmologic syndrome: Report of two cases.
Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.
Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate.
Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions.
The potential role of subclinical Bordetella Pertussis colonization in the etiology of multiple sclerosis.
Functional involvement of γ-secretase in signaling of the triggering receptor expressed on myeloid cells-2 (TREM2).
C-C chemokine receptor type 4 antagonist Compound 22 ameliorates experimental autoimmune encephalomyelitis.
Charles bonnet syndrome after herpes simplex encephalitis.
Gait characteristics of multiple sclerosis patients in the absence of clinical disability.
Re. 'Doppler Ultrasound Examination of Multiple Sclerosis Patients and Control Participants: Inter-observer Agreement and Association with Disease'
Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence.
Morphologic features of the binucleated lymphocytes for the assesment of persistent B-cell polyclonal lymphocytosis.
Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.

Pages